Form 4: Equillium Inc. Executive Zedelmayer Christine Reports Option Repricing and Subsequent Transactions
SEC Form 4 Filing
Christine Zedelmayer, Sr. Vice President and COO of Equillium, Inc., reports the repricing of employee stock options and related transactions following the lapse of a holding period.
Summary
- This Form 4 filing details changes in beneficial ownership for Christine Zedelmayer, Sr. Vice President and COO of Equillium, Inc.
- On February 14, 2025, Zedelmayer engaged in transactions related to employee stock options.
- These transactions involve the acquisition and disposal of derivative securities (employee stock options) due to the lapse of a holding period following a repricing approved by the Board of Directors on August 7, 2023.
- The repricing, based on the closing price of Equillium's common stock on August 14, 2023, resulted in a lower exercise price of $0.785 per share for certain options.
- The filing covers options with varying exercise prices ($0.785, $1.06, $2.45, $3.86, $5.03) and expiration dates (September 12, 2028, February 12, 2029, December 9, 2029, January 3, 2031, January 18, 2032, January 2, 2033).
- The options vest 25% on the first anniversary of the vesting commencement date, with the remainder vesting in 36 equal monthly installments over the following three years.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing is a standard disclosure of executive stock option transactions. The repricing itself could be seen as a response to previous underperformance, but the long-term vesting schedule suggests a commitment to future growth.
Positives
- The repricing of options at $0.785 may incentivize Zedelmayer to improve company performance.
- The long vesting schedules (up to 2033) align Zedelmayer's interests with the long-term success of Equillium.
Future Outlook
The document does not contain explicit forward-looking statements, but the option vesting schedules suggest a long-term commitment from the executive.
Industry Context
Option repricing is a tool companies sometimes use to re-incentivize employees when the stock price has fallen significantly. It's a way to maintain motivation and retain talent.
Comparison to Industry Standards
- Option repricing is a relatively common practice in the biotech industry, especially for companies with volatile stock prices.
- Companies like Amgen, Gilead, and Biogen also use stock options as a key component of executive compensation.
- The vesting schedules described are fairly standard, aligning with typical industry practices for incentivizing long-term performance.
Stakeholder Impact
- Shareholders may view the option repricing as a way to re-incentivize management.
- Employees holding options will benefit from the lower exercise price.
- The long-term vesting schedule aligns management's interests with those of long-term shareholders.
Key Dates
| Date | Description |
|---|---|
| August 7, 2023 | Board of Directors approved the repricing of certain options. |
| August 14, 2023 | Closing price of Equillium's common stock used for option repricing ($0.785). |
| February 14, 2025 | Date of transactions reported in the Form 4; holding period lapsed. |
| September 12, 2028 | Expiration date of some employee stock options. |
| February 12, 2029 | Expiration date of some employee stock options. |
| December 9, 2029 | Expiration date of some employee stock options. |
| January 3, 2031 | Expiration date of some employee stock options. |
| January 18, 2032 | Expiration date of some employee stock options. |
| January 2, 2033 | Expiration date of some employee stock options. |
Keywords
Form 4, Equillium, Stock Options, Repricing, Beneficial Ownership, Zedelmayer, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.